Suppr超能文献

欧洲家庭肠外营养患者的长期随访:对肠移植的影响。

Long-term follow-up of patients on home parenteral nutrition in Europe: implications for intestinal transplantation.

机构信息

Center for Chronic Intestinal Failure, Department of Gastroenterology and Internal Medicine, University of Bologna, Italy.

出版信息

Gut. 2011 Jan;60(1):17-25. doi: 10.1136/gut.2010.223255. Epub 2010 Nov 10.

Abstract

BACKGROUND

The indications for intestinal transplantation (ITx) are still debated. Knowing survival rates and causes of death on home parenteral nutrition (HPN) will improve decisions.

METHODS

A prospective 5-year study compared 389 non-candidates (no indication, no contraindication) and 156 candidates (indication, no contraindication) for ITx. Indications were: HPN failure (liver failure; multiple episodes of catheter-related venous thrombosis or sepsis; severe dehydration), high-risk underlying disease (intra-abdominal desmoids; congenital mucosal disorders; ultra-short bowel), high morbidity intestinal failure. Causes of death were defined as: HPN-related, underlying disease, or other cause.

RESULTS

The survival rate was 87% in non-candidates, 73% in candidates with HPN failure, 84% in those with high-risk underlying disease, 100% in those with high morbidity intestinal failure and 54%, in ITx recipients (one non-candidate and 21 candidates) (p<0.001). The primary cause of death on HPN was underlying disease-related in patients with HPN duration ≤2 years, and HPN-related in those on HPN duration >2 years (p=0.006). In candidates, the death HRs were increased in those with desmoids (7.1; 95% CI 2.5 to 20.5; p=0.003) or liver failure (3.4; 95% CI 1.6 to 7.3; p=0.002) compared to non-candidates. In deceased candidates, the indications for ITx were the causes of death in 92% of those with desmoids or liver failure, and in 38% of those with other indications (p=0.041). In candidates with catheter-related complications or ultra-short bowel, the survival rate was 83% in those who remained on HPN and 78% after ITx (p=0.767).

CONCLUSIONS

HPN is confirmed as the primary treatment for intestinal failure. Desmoids and HPN-related liver failure constitute indications for life-saving ITx. Catheter-related complications and ultra-short bowel might be indications for pre-emptive/rehabilitative ITx. In the early years after commencing HPN a life-saving ITx could be required for some patients at higher risk of death from their underlying disease.

摘要

背景

肠移植(ITx)的适应证仍存在争议。了解接受家庭肠外营养(HPN)治疗患者的生存率和死亡原因将有助于决策。

方法

前瞻性 5 年研究比较了 389 例非候选者(无适应证、无禁忌证)和 156 例候选者(适应证、无禁忌证)用于 ITx。适应证为:HPN 失败(肝功能衰竭;多次导管相关静脉血栓形成或脓毒症;严重脱水)、高危基础疾病(腹内纤维瘤;先天性黏膜疾病;极短肠)、高发病率肠衰竭。死亡原因定义为:HPN 相关、基础疾病或其他原因。

结果

非候选者的生存率为 87%,HPN 失败的候选者为 73%,高危基础疾病的候选者为 84%,高发病率肠衰竭的候选者为 100%,接受 ITx 的患者为 54%(1 例非候选者和 21 例候选者)(p<0.001)。HPN 持续时间≤2 年的患者 HPN 相关的基础疾病是 HPN 相关死亡的主要原因,而 HPN 持续时间>2 年的患者 HPN 相关死亡的主要原因(p=0.006)。在候选者中,与非候选者相比,纤维瘤(7.1;95%CI 2.5 至 20.5;p=0.003)或肝功能衰竭(3.4;95%CI 1.6 至 7.3;p=0.002)患者的死亡风险比更高。在死亡的候选者中,92%的纤维瘤或肝功能衰竭患者以及 38%的其他适应证患者的 ITx 适应证为其死亡原因(p=0.041)。在发生导管相关并发症或极短肠的候选者中,继续接受 HPN 治疗的患者的生存率为 83%,接受 ITx 治疗的患者的生存率为 78%(p=0.767)。

结论

HPN 被证实为肠衰竭的主要治疗方法。纤维瘤和 HPN 相关的肝功能衰竭构成了挽救生命的 ITx 的适应证。导管相关并发症和极短肠可能是预防性/康复性 ITx 的适应证。在开始 HPN 的早期,一些高危基础疾病患者可能需要进行挽救生命的 ITx。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验